<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193192</url>
  </required_header>
  <id_info>
    <org_study_id>N-002</org_study_id>
    <nct_id>NCT01193192</nct_id>
  </id_info>
  <brief_title>A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy</brief_title>
  <official_title>A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pamlab, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norman Regional Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Five Oaks Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pamlab, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-site, retrospective chart review to determine the effect of Neevo® or
      NeevoDHA® (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb)
      levels in pregnant women throughout the course of pregnancy. Neevo® is a prescription medical
      food indicated for the dietary management of women under a doctor's care who face high risk
      pregnancies, older overactive bladder (OB) patients and patients unable to fully metabolize
      folic acid. Data will be collected from existing patient charts of subjects administered
      Neevo® or NeevoDHA® daily compared to subjects administered a prenatal vitamin daily.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate number of charts available for Test Group
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Hemoglobin (Hgb) Levels</measure>
    <time_frame>At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.</time_frame>
    <description>To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on mean hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hemoglobin (Hgb) Levels</measure>
    <time_frame>At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.</time_frame>
    <description>To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on mean change in hemoglobin levels in pregnant women.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anemia</measure>
    <time_frame>At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.</time_frame>
    <description>To determine if Neevo®/NeevoDHA® administration during pregnancy results in fewer incidences of anemia than with standard prenatal vitamins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pre-eclampsia</measure>
    <time_frame>At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.</time_frame>
    <description>To determine if Neevo®/NeevoDHA® administration during pregnancy results in fewer cases of pre-eclampsia than with standard prenatal vitamins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Infant Birth Rate</measure>
    <time_frame>At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.</time_frame>
    <description>To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on infant birth weight.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Anemia in Pregnancy</condition>
  <condition>Pre-eclampsia</condition>
  <arm_group>
    <arm_group_label>Arm #1 (Test Group)</arm_group_label>
    <description>100 subject administered Neevo® or NeevoDHA® daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #2 (Control group)</arm_group_label>
    <description>100 subject administered a prenatal vitamin daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neevo®</intervention_name>
    <description>A prenatal &quot;medical food&quot; - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid</description>
    <arm_group_label>Arm #1 (Test Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prenatal vitamins</intervention_name>
    <description>for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.</description>
    <arm_group_label>Arm #2 (Control group)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Women Who Received Neevo®/NeevoDHA® or Another Standard Prenatal Vitamin
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant females, age 21-39, who received either Neevo®/NeevoDHA® or another standard
             prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and
             ≤12mcg vitamin B12).

          -  Clinical diagnosis of pregnancy must have been made at ≤12 weeks of Pregnancy, and
             delivery must have occurred on or after January 1, 2008 and on or before March 31,
             2010

          -  Subjects must have been compliant in taking Neevo®/NeevoDHA® or other prenatal vitamin

        Exclusion Criteria:

          -  Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are
             L-methylfolate-containing prenatal vitamins.

          -  The following supplements within 2 months of diagnosis of pregnancy: B12 injection; &gt;
             35mg Iron; &gt; 1.2 mg of folate; or a L-methylfolate product that is not a prenatal
             vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF,
             Metanx®, Deplin®, Cerefolin®, or CerefolinNAC®

          -  History of leukemia or any anemia other than iron deficiency anemia or;

          -  Taking any iron supplement (in addition to the prenatal vitamin) prior to Week 22
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Jarvis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norman Regional Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Five Oaks Medical Group</name>
      <address>
        <city>Chickasha</city>
        <state>Oklahoma</state>
        <zip>73018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norman Regional Health System</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norman Regional Health System</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neevo</keyword>
  <keyword>Neevo DHA</keyword>
  <keyword>L-methylfolate</keyword>
  <keyword>anemia during pregnancy</keyword>
  <keyword>folic acid</keyword>
  <keyword>vitamin B12</keyword>
  <keyword>prenatal vitamins</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>iron deficiency</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

